BjorndalBTunglandSLBohovPSydnesMODankelSNMadsenLet al
prescription drugs
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have become cornerstone drug classes in the treatment of type 2 diabetes1516 owing to their cardiovascular and kidney benefits.17181920 Post hoc analyses of randomized trials have recently shown that SGLT-2 inhibitors also lower the risk of hyperkalemia compared with placebo, an outcome that was not defined as primary or secondary in those trials.212223 However, we do not know whether these benefits are also observed outside the highly controlled setting of randomized trials, and whether all agents within the SGLT-2 inhibitor class similarly reduce the risk of hyperkalemia
Sermorelin: A Review of its Use in the Diagnosis and Treatment of Children with Idiopathic Growth Hormone Deficiency
It is proposed to work by binding GHRH receptors on pituitary somatotroph cells, prompting the pituitary to synthesize and release its own growth hormone in a pulsatile pattern, with the body's somatostatin feedback loop still intact so the effect is self-limiting rather than a constant hormone flood
In addition, there is considerable evidence that estrogen increases substantially the activities of GPX and Glutamate Cysteine Ligase (GCL), an enzyme in the GSH pathway [5-7]